Investigational product portfolio

BGB-43395 CDK4

• Phase 1: Breast cancer

BG-68501* CDK2

• Phase 1: Breast cancer

BG-C9074^† B7H4-ADC

• Phase 1: Breast cancer

Zanidatamab^‡ HER2 BsAb

• Phase 1: 1L metastatic breast cancer

Goserelin microspheres^§ GnRH agonist

• Phase 3: Breast cancer

Zanidatamab^‡ HER2 BsAb

• Phase 1: Gastric cancer
• Phase 3: 1L HER2+ GEA

LBL-007^|| LAG3

• Phase 2: 1L ESCC

Tislelizumab PD-1

• Phase 3: Locally advanced ESCC
• Registration studies (US only): 1L gastric cancer/GEJC; 1L ESCC

LBL-007^|| LAG3

• Phase 2: MSS-CRC

Xaluritamig^¶ STEAP1 x CD3

• Phase 1: mCRPC (initiation activities)

Goserelin microspheres^§ GnRH agonist

• Phase 3: Prostate cancer

Ociperlimab TIGIT

• Phase 2: 1L NSCLC
• Phase 3: 1L NSCLC PD-L1 high

Tislelizumab PD-1

• Phase 1: NSCLC (subcutaneous formulation)
• Phase 2: 1L NSCLC, 2L+ NSCLC, neoadjuvant NSCLC (umbrella study)^4,#
• Phase 3: Neo/adjuvant NSCLC^**
• Phase 3: 1L nonsquamous NSCLC, 1L squamous NSCLC, 2L+ NSCLC
• Phase 3: 1L ES-SCLC

Tarlatamab^¶ DLL3 x CD3

• Phase 3: 2L SCLC, 1L ES-SCLC (initiation activities), LS-SCLC (initiation activities), 3L+ SCLC

BGB-A445 OX40

• Phase 2: Melanoma, RCC, urothelial carcinoma

Tislelizumab PD-1

• Phase 2: 1L HNSCC (umbrella study)^5,#
• Phase 3: 1L HCC, 2L+ HCC
• Phase 3: 1L NPC
• Phase 3: 1L UBC

Zanidatamab^‡ HER2 BsAb

• Phase 2: HER2+ 2L BTC

Pamiparib PARP

• Phase 2: Advanced ovarian cancer
• Phase 3: 2L methotrexate gBRCAm PSOC

Surzebiclimab TIM-3

• Phase 2: 1L HNSCC

Blinatumomab^¶ CD3 x CD19

• Phase 2: Pediatric R/R BP-ALL (initiation activities)

Ociperlimab TIGIT

• Phase 1: Solid tumors

BGB-15025/26808 HPK1

• Phase 1: Solid tumors

BGB-30813 DGKζ

• Phase 1: Solid tumors

BGB-A3055 CCR8

• Phase 1: Solid tumors

BGB-24714 SMAC mimetic

• Phase 1: Solid tumors

BGB-10188 PI3Kδ

• Phase 1: Solid tumors

BGB-43395 CDK4

• Phase 1: Solid tumors

BG-68501^* CDK2

• Phase 1: Solid tumors

BG-C9074^† B7H4-ADC

• Phase 1: Solid tumors